Cranial prophylactic irradiation in locally advanced non-small cell lung carcinoma: Current status and future perspectives

Oncology

Volumn 76, Issue 3, 2009, Pages 220-228

  Topkan, Erkan ^a   Yildirim, Berna Akkus ^b   Selek, Ugur ^c   Yavuz, Melek Nur ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Brain metastases; Cranial prophylactic irradiation; Non small cell lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 8; CISPLATIN; EPHRIN A2; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; MITOMYCIN; PLATINUM; PROTEIN P53; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; UVOMORULIN; VINBLASTINE;

ADVANCED CANCER; BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DEMENTIA; DRUG PENETRATION; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SKULL IRRADIATION;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COGNITION; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY DOSAGE; THORAX; TIME FACTORS;

EID: 59749101889     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201933     Document Type: Review

References (63)

1. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-1892.
2. Eberhardt W, Wilke H, Stuschke M, Stuschke M, Harstrick A, Menker H, Krause B, Müeller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiation therapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-634.
3. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, Lynch T, Grossbard M, Grillo H: Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol 1997;15:712-722.
4. Law A, Daly B, Madsen M, et al: High incidence of isolated brain metastases (CNS Mets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): a new challenge (abstract 1604). Proc Am Soc Clin Oncol 1997;16:447.
5. Cox JD, Scott CB, Byhardt RW, Emami B, Russell AH, Fu KK, Parliament MB, Komaki R, Gaspar LE: Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1999;43:505-509.
6. Stuschke M, Eberhardt W, Pottgen C, Stamatis G, Wilke H, Stüben G, Stöblen F, Wilhelm HH, Menker H, Teschler H, Müller RD, Budach V, Seeber S, Sack H: Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999;17:2700-2709.
7. Andre F, Grunenwald D, Pujol JL, Girard P, Dujon A, Brouchet L, Brichon PY, Westeel V, Le Chevalier T: Patterns of relapse of N2 non-small-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer 2001;91:2394-2400.
8. Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992;10:1237-1244.
9. Rusch VW, Griffin BR, Livingston RB: The role of prophylactic cranial irradiation in regionally advanced non-small cell lung cancer. A Southwest Oncology Group Study. J Thorac Cardiovasc Surg 1989;98:535-539.
10. Skarin A, Jochelson M, Sheldon T, Malcolm A, Oliynyk P, Overholt R, Hunt M, Frei E 3rd: Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989;40:266-274.
11. Russell AH, Pajak TE, Selim HM, Paradelo JC, Murray K, Bansal P, Cooper JD, Silverman S, Clement JA: Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991;21:637-643.
12. Umsawasdi T, Valdivieso M, Chen TT, Barkley HT Jr, Booser DJ, Chiuten DF, Dhingra HM, Murphy WK, Dixon CL, Farha P: Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol 1984;2:253-259.
13. Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R: Cranial irradiation in cancer of the lung of all cell types. JAMA 1981;245:469-472.
14. Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M: Prophylactic cranial irradiation in operable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter trial. J Clin Oncol 2007;25:4987-4992.
15. Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM: Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 2001;19:1344-1349.
16. Law A, Karp DD, Dipetrillo T, Daly BT: Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced non-small cell lung carcinoma. Cancer 2001;92:160-164.
17. Ceresoli GL, Reni M, Chiesa G, Carretta A, Schipani S, Passoni P, Bolognesi A, Zannini P, Villa E: Brain metastases in locally advanced non-small cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 2002;95:605-612.
18. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR: Time from treatment to subsequent diagnosis of brain metastasis in stage III non-small-cell lung cancer. A retrospective review by the Southwest Oncology Group. J Clin Oncol 2005;23:2955-2961.
19. Mamon HJ, Yeap BY, Janne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R: High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530-1537.
20. Schouten LJ, Rutten J, Huveneers HA, Twinjstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-2705.
21. Carolan H, Sun AY, Bezjak A, Yi QL, Payne D, Kane G, Waldron J, Leighl N, Feld R, Burkes R, Keshavjee S, Shepherd F: Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 2005;49:109-115.
22. Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin JC, Depierre A: Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 2004;45:317-323.
23. Komaki R, Scott CB, Byhardt R, Emami B, Asbell SO, Russell AH, Roach M, Parliament MB, Gaspar LE: Failure patterns by prognostic group determined by recursive partitioning analysis of 1547 patients on four RTOG studies in inoperable non small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;42:263-267.
24. Keith B, Vincent M, Stitt L, Tomiak A, Malthaner R, Yu E, Truong P, Inculet R, Lefcoe M, Dar AR, Kocha W, Craig I: Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small cell lung cancer. Am J Clin Oncol 2002;25:583-587.
25. Jacobs RH, Awan A, Bitran JD, Hoffman PC, Little AG, Ferguson MK, Weichselbaum R, Golomb HM: Prophylactic cranial irradiation in adenocarcinoma of the lung: a possible role. Cancer 1987;59:2016-2019.
26. Tang SG, Lin FJ, Leung VM: Impact of cranial irradiation in adenocarcinoma of the lung. J Formos Med Assoc 1993;92:413-419.
27. Milleron B, Guigay J, Rugeri L, Rosencher L, Terrioux P, Beerblock K, Akoun G: Le bilan d'extension des adenocarcinomes bronchiques doit-il differer de celui des autres cancers bronchiques non a petites cellulies? Rev Pneumol Clin 1992;48:159-162.
28. Salbeck R, Grau HC, Artmann H: Cerebral tumor staging in patients with bronchial carcinoma by computed tomography. Cancer 1990;66:2007-2011.
29. Salvatierra A, Bahamonde C, Llamas J, Cruz F, Lopez-Pujol J: Extrathoracic staging of bronchogenic carcinoma. Chest 1990;97:1052-1058.
30. Arriagada R, Le Chevalier T, Quiox E, Ruffie P, de Cremoux H, Douillard JY, Tarayre M, Pignon JP, Laplanche A: ASTRO plenary. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study on 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 1991;20:1183-1190.
31. Non Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated individual patient data from 52 randomised clinical trials. BMJ 1995;311:899-909.
32. Kumar P, Herndon J II, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ, et al: Patterns of disease failure after trimodality therapy of non small cell lung carcinoma pathologic stage IIIa (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer 1996;77:2393-2399.
33. Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA: Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.
34. The International Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
35. Postmus PE, Smit EF: Chemotherapy for brain metastases of lung cancer. A review. Ann Oncol 1999;10:753-759.
36. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG: A phase II trial of temozolamide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-265.
37. Schutte W, Manegold C, Von Pawl JV, Lan J, Schäfer B, Kaubitzsch S, Staab HJ: Topotecan: a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 1999;33:354-363.
38. Griffin BR, Livingston RB, Stewart GR, Higano C, Russell KJ, Griffin TW, Laramore GE: Prophylactic cranial irradiation for limited non-small cell lung cancer. Cancer 1988;62:36-39.
39. Ceresoli GL, Gregorc V, Cappuzzo F, et al: ZD 1839 in non-small cell lung cancer (NSCLC) patients with brain metastases (BM) (abstract 2709). Proc Am Soc Clin Oncol 2003;22:674.
40. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr: Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001;72:1144-1148.
41. Bubb RS, Komaki R, Hachiya T, Milas I, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L: Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys 2002;53:1216-1224.
42. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
43. Ohshima K, Hamasaki M, Makimoto Y, Yoneda S, Fujii A, Takamatsu Y, Nakashima M, Watanabe T, Kawahara K, Kikuchi M, Shirakusa T: Differential chemokine, chemokine receptor, cytokine and cytokine receptor expression in pulmonary adenocarcinoma: diffuse down-regulation is associated with immune evasion and brain metastasis. Int J Oncol 2003;23:965-973.
44. Balkwill F: Cancer and chemokine network. Nat Rev Cancer 2004;4:540-550.
45. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-1686.
46. Altundag O, Altundag K, Morandi P, Gunduz M: Cytokines and chemokines as predictive markers in non-small cell lung cancer patients with brain metastases. Lung Cancer 2004;47:291-292.
47. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS: Antibody targeting of the EphA2 receptor tyrosine kinase on malignant carcinomas. Cancer Res 2001;62:2840-2847.
48. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000;19:6043-6052.
49. Kinch MS, Moore MB, Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9:613-618.
50. Mira JG, Miller TP, Crowley JJ: Chest irradiation vs. chest irradiation plus chemotherapy with or without cranial prophylactic brain radiotherapy in localized non small cell lung cancer. A South West Oncology Group randomized study. Int J Radiat Oncol Biol Phys 1990;19:145.
51. Suwinski R, Lee SP, Withers R: Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;40:797-806.
52. Cull A, Gregor A, Hopwood P, Macbeth F, Karnicka-Mlodkowska H, Thatcher N, Burt P, Stout R, Stepniewska K, Stewart M: Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur J Cancer 1994;30:1067-1074.
53. Johnson BE, Becker B, Goff WB II, Petronas N, Krehbiel MA, Makuch RW, McKenna G, Glatstein E, Ihde DC: Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J Clin Oncol 1985;3:1659-1667.
54. Johnson BE, Petronas N, Hayes W, Grayson J, Becker B, Gnepp D, Rowland J, Anderson A, Glatstein E, Ihde DC: Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol 1990;8:48-56.
55. van Oosterhout AG, van de Pol M, ten Velde GP, Twijnstra A: Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer 1996;77:1434-1441.
56. Auperin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
57. Arriagada R, Le Chevalier T, Borie F, Rivière A, Chomy P, Monnet I, Tardivon A, Viader F, Tarayre M, Benhamou S: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-190.
58. Gregor A, Cull A, Stephens RJ, Kirkpatrick JA, Yarnold JR, Girling DJ, Macbeth FR, Stout R, Machin D: Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997;33:1752-1758.
59. Roman DD, Sperduto PW: Neuropsychological effects of cranial radiation: current knowledge and future directions. Int J Radiat Oncol Biol Phys 1995;31:983-998.
60. De Angelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789-796.
61. Abayomi OK: Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncol 1996;35:659-663.
62. Monje ML, Mizumatsu S, Fike JR: Irradiation induces neural precursor-cell dysfunction. Nat Med 2002;8:955-962.
63. Gutierrez AN, Westerly DC, Tome WA, Jaradat HA, Mackie TR, Bentzen SM, Khuntia D, Mehta MP: Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 2007;69:589-597.